151 related articles for article (PubMed ID: 26318424)
1. Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
Sun NK; Huang SL; Lu HP; Chang TC; Chao CC
Oncotarget; 2015 Sep; 6(29):27065-82. PubMed ID: 26318424
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.
Sun NK; Huang SL; Chang PY; Lu HP; Chao CC
Oncotarget; 2014 Dec; 5(23):11939-56. PubMed ID: 25460502
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.
Sun NK; Kohli A; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2019 Jun; 234(6):8760-8775. PubMed ID: 30317630
[TBL] [Abstract][Full Text] [Related]
4. H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.
Kohli A; Huang SL; Chang TC; Chao CC; Sun NK
Cancer Sci; 2022 Aug; 113(8):2616-2626. PubMed ID: 35639349
[TBL] [Abstract][Full Text] [Related]
5. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
6. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2020 Jul; 177():113965. PubMed ID: 32278794
[TBL] [Abstract][Full Text] [Related]
7. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract][Full Text] [Related]
8. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of taxol-resistant nasopharyngeal carcinoma cells with siRNA-mediated FOLR1 downregulation.
Song Y; Peng X; Wang M; Xie J; Tan G
Int J Clin Exp Pathol; 2015; 8(9):11314-22. PubMed ID: 26617855
[TBL] [Abstract][Full Text] [Related]
10. Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity.
Huang SL; Chang TC; Sun NK
Biochem Pharmacol; 2023 Jun; 212():115581. PubMed ID: 37146834
[TBL] [Abstract][Full Text] [Related]
11. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
[TBL] [Abstract][Full Text] [Related]
12. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M
Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway.
Zhang X; Ling MT; Wang X; Wong YC
Int J Cancer; 2006 Apr; 118(8):2072-81. PubMed ID: 16287090
[TBL] [Abstract][Full Text] [Related]
14. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
15. Amplification of chromosome 8q21-qter associated with the acquired paclitaxel resistance of nasopharyngeal carcinoma cells.
Li W; You Y; Zhang X; Song Y; Xiang H; Peng X; Qin J; Tan G
Int J Clin Exp Pathol; 2015; 8(10):12346-56. PubMed ID: 26722421
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
18. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
